* Agennix Inc., of Houston, received three patents (Nos. 5,571,691;5,571,896; and 5,571,697) covering production of recombinanthuman lactoferrin.
* Alexion Pharmaceuticals Inc., of New Haven, Conn., receivedpatent No. 5,573,940, titled "Cells expressing high levels of CD59,"covering genetic engineering of mammalian cells with humancomplement inhibitor. The procedure is related to Alexion's work inxenotransplantation.
* Alfacell Corp., of Bloomfield, N.J., received patent No. 5,559,212,titled "Frog embryo and egg-derived tumor cell anti-proliferationprotein," for the amino acid sequence of Onconase, the company'slead anti-cancer drug. Onconase is an RNase protein.
* Ansan Inc., of South San Francisco, received patent No. 5,569,675,covering the use of the company's Novaheme injection for red bloodcell disorders. Novaheme, an analogue of butyrate, is designed tostimulate hemoglobin F production in red blood cells.
* Biometric Imaging Inc., of Mountain View, Calif., received twopatents related to the company's microvolume fluorimetry technologyplatform for cellular analysis.
* Diatide Inc., of Londonderry, N.H., received two patents fortechnologies related to its P483H Techtide for pinpointing internalinfections. P483H combines a polybasic platelet factor 4-derivedpeptide compound with heparin, a polysulfated glycan. The patentscover radiopharmaceuticals comprising peptides from platelet factor4 and polybasic compounds combined with polysulfated glycans.
* Dyax Corp., of Cambridge, Mass., received patent No. 5,571,698,covering methods and intermediates for the display of geneticdiversity on cells, spores and viruses.
* GenPharm International Inc., of Palo Alto, Calif., received twopatents for transgenic mice production of human antibodies: No.5,545,806 covers methods of producing human antibodies intransgenic mice; and No. 5,569,825 covers the transgenic mice.
* Genta Inc., of San Diego, received notice of allowance for a patenton antisense compounds targeting the apoptosis gene, BCL2, whichis linked to solid tumor and hematological malignancies.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., received 11 patentsrelated to its antisense and combinatorial chemistry technologies. Thepatents are: No. 5,506,212, titled "Oligonucleotides havingsubstantially chirally pure phosphorothioate linkages"; No.5,521,302, "Process for preparing oligonucleotides having chiralphosphorous linkages"; No. 5,541,307, "Backbone modifiedoligonucleotide analogs and solid phase synthesis thereof"; No.5,510,476, "Carbocation scavenging during oligonucleotidesynthesis"; No. 5,514,786, "Compositions for inhibiting RNAactivity"; No. 5,543,507, "Covalently cross-linked oligonucleotides";No. 5,512,438, "Inhibiting RNA expression by forming a pseudo-half-knot RNA at the target's RNA secondary structure usingantisense oligonucleotides"; No. 5,510,239, "Oligonucleotidemodulation of multidrug resistance associated protein"; No.5,514,577, "Improved oligonucleotide therapies for modulating theeffects of herpesviruses"; No. 5,519,134, "Prolinol synthons forpreparation of oligonucleotides mimics"; and No. 5,554,746,"Synthesis of lactam nucleic acids."
* Oxford Molecular Group plc., of London, received patent No.5,577,239 for its Relational Structure Search System RS3 Discoverysoftware for chemical information management.
* Tularik Inc., of South San Francisco, received two patents: No.5,563,036 covers development and use of in vitro transcription factorbinding assays; and No. 5,563,039 relates to a component of thetumor necrosis factor signaling pathway.
* Xoma Corp., of Berkeley, Calif., received three patents (Nos.5,576,292; 5,578,568; and 5,578,572) related to the company'sbactericidal permeability-increasing (BPI) protein, a human host-defense protein. Xoma is developing drugs derived from BPI forinfections and immunological disorders.
(c) 1997 American Health Consultants. All rights reserved.